Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination

Amal Hasan; Mohammad R. Al-Mulla; Jehad Abubaker; Fahd Al-Mulla

doi:10.1080/21645515.2021.1969855

Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination

Amal Hasan, Mohammad R. Al-Mulla, Jehad Abubaker, Fahd Al-Mulla

Dasman Diabetes Institute

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8⁺T-cell immunity.

Original language	English
Pages (from-to)	4121-4125
Number of pages	5
Journal	Human Vaccines and Immunotherapeutics
Volume	17
Issue number	11
DOIs	https://doi.org/10.1080/21645515.2021.1969855
State	Published - 2021

Keywords

COVID-19
SARS-CoV-2
antibodies
antibody-dependent enhancement
neutralization
spike protein
vaccine

Funding Agency

Kuwait Foundation for the Advancement of Sciences

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1080/21645515.2021.1969855

Cite this

@article{28cf6473a9bd42158920e2bdb487b5f4,

title = "Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination",

abstract = "Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity.",

keywords = "COVID-19, SARS-CoV-2, antibodies, antibody-dependent enhancement, neutralization, spike protein, vaccine",

author = "Amal Hasan and Al-Mulla, \{Mohammad R.\} and Jehad Abubaker and Fahd Al-Mulla",

note = "Publisher Copyright: {\textcopyright} 2021 Taylor \& Francis Group, LLC.",

year = "2021",

doi = "10.1080/21645515.2021.1969855",

language = "English",

volume = "17",

pages = "4121--4125",

journal = "Human Vaccines and Immunotherapeutics",

issn = "2164-5515",

publisher = "Taylor and Francis Ltd.",

number = "11",

}

TY - JOUR

T1 - Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination

AU - Hasan, Amal

AU - Al-Mulla, Mohammad R.

AU - Abubaker, Jehad

AU - Al-Mulla, Fahd

PY - 2021

Y1 - 2021

N2 - Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity.

AB - Current vaccines, which induce a B-cell-mediated antibody response against the spike protein of SARS-CoV-2, have markedly reduced infection rates. However, the emergence of new variants as a result of SARS-CoV-2 evolution requires the development of novel vaccines that are T-cell-based and that target mutant-specific spike proteins along with ORF1ab or nucleocapsid protein. This approach is more accommodative in inducing highly neutralizing antibodies, without the risk of antibody-dependent enhancement, as well as memory CD8+T-cell immunity.

KW - COVID-19

KW - SARS-CoV-2

KW - antibodies

KW - antibody-dependent enhancement

KW - neutralization

KW - spike protein

KW - vaccine

UR - https://www.scopus.com/pages/publications/85115226582

U2 - 10.1080/21645515.2021.1969855

DO - 10.1080/21645515.2021.1969855

M3 - Article

C2 - 34543154

AN - SCOPUS:85115226582

SN - 2164-5515

VL - 17

SP - 4121

EP - 4125

JO - Human Vaccines and Immunotherapeutics

JF - Human Vaccines and Immunotherapeutics

IS - 11

ER -

Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination

Abstract

Keywords

Funding Agency

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this